Plasma β-amyloid and MRI markers of cerebral small vessel disease

Neurology

Volumn 83, Issue 22, 2014, Pages 2038-2045

  Kaffashian, Sara ^a   Tzourio, Christophe ^a   Soumaré, Aïcha ^a   Dufouil, Carole ^a   Zhu, Yicheng ^a,b   Crivello, Fabrice ^a   Maillard, Pauline ^c   Schraen Maschke, Susanna ^d,e   Mazoyer, Bernard ^a   Buée, Luc ^d,e   Debette, Stéphanie ^a,f,g  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; AGING; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BRAIN; CEREBROVASCULAR DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; SPACE; VERY ELDERLY; WHITE MATTER; BLOOD; CEREBRAL SMALL VESSEL DISEASES; FRANCE; LONGITUDINAL STUDY; TRENDS;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CEREBRAL SMALL VESSEL DISEASES; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; PEPTIDE FRAGMENTS;

EID: 84922481457     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001038     Document Type: Article

References (40)

1. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013; 12: 483-497.
2. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010; 341: c3666.
3. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007; 6: 611-619.
4. Zhu YC, Dufouil C, Soumare A, Mazoyer B, Chabriat H, Tzourio C. High degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of dementia. J Alzheimers Dis 2010; 22: 663-672.
5. Schmidt R, Ropele S, Enzinger C, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian Stroke Prevention Study. Ann Neurol 2005; 58: 610-616.
6. Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011; 70: 871-880.
7. Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbruegg S, Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol Aging 2009; 30: 1936-1948.
8. Yoshita M, Fletcher E, Harvey D, et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006; 67: 2192-2198.
9. Jellinger KA, Mitter-Ferstl E. The impact of cerebrovascular lesions in Alzheimer disease: a comparative autopsy study. J Neurol 2003; 250: 1050-1055.
10. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004; 35: 2616-2619.
11. Sagare AP, Bell RD, Zlokovic BV. Neurovascular defects and faulty amyloid-beta vascular clearance in Alzheimer's disease. J Alzheimers Dis 2013; 33(suppl 1): S87-S100.
12. Rutten-Jacobs LC, de Leeuw FE, Geurts-van Bon L, et al. White matter lesions are not related to beta-amyloid deposition in an autopsy-based study. Curr Gerontol Geriatr Res 2011; 2011: 826862.
13. Marchant NL, Reed BR, DeCarli CS, et al. Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiol Aging 2012; 33: e1025-e1036.
14. van Dijk EJ, Prins ND, Vermeer SE, et al. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004; 55: 570-575.
15. Gurol ME, Irizarry MC, Smith EE, et al. Plasma betaamyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006; 66: 23-29.
16. Toledo JB, Vanderstichele H, Figurski M, et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011; 122: 401-413.
17. Stenset V, Johnsen L, Kocot D, et al. Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42. Neurology 2006; 67: 830-833.
18. Fornage M, Debette S, Bis JC, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011; 69: 928-939.
19. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144.
20. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, Montine TJ. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 2008; 7: 704-714.
21. Grimmer T, Faust M, Auer F, et al. White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol Aging 2012; 33: 2766-2773.
22. Huang YH, Zhang WW, Lin L, et al. Could changes in arterioles impede the perivascular drainage of interstitial fluid from the cerebral white matter in leukoaraiosis? Neuropathol Appl Neurobiol 2010; 36: 237-247.
23. O'Sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology 2002; 59: 321-326.
24. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519.
25. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-360.
26. Park L, Zhou P, Koizumi K, et al. Brain and circulating levels of Abeta1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke 2013; 44: 198-204.
27. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis Assoc Disord 2002; 16: 187-190.
28. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002; 295: 2264-2267.
29. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009; 65: 176-183.
30. Lambert JC, Schraen-Maschke S, Richard F, et al. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 2009; 73: 847-853.
31. Bouras C, Kovari E, Herrmann FR, et al. Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J Neuropathol Exp Neurol 2006; 65: 235-244.
32. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005; 234: 851-859.
33. Gurol ME, Viswanathan A, Gidicsin C, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 2013; 73: 529-536.
34. Chen YW, Gurol ME, Rosand J, et al. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology 2006; 67: 83-87.
35. Peca S, McCreary CR, Donaldson E, et al. Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology 2013; 81: 1659-1665.
36. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492-498.
37. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD Sr, Diaz-Arrastia R, Park DC. Risk factors for beta-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013; 70: 600-606.
38. Shah NS, Vidal JS, Masaki K, et al. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension 2012; 59: 780-786.
39. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487-499.
40. Park L, Zhou J, Zhou P, et al. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc Natl Acad Sci USA 2013; 110: 3089-3094.